Laura C. Michaelis, MD: In My Experience Question 3

The ASCO Post Staff

Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.

The ASCO Post Staff

Saad Z. Usmani, MD: In My Experience Question 3

Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma?

Recorded April 24, 2020.

The ASCO Post Staff

Mehdi Hamadani, MD: In My Experience Question 2

During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission?

Recorded April 21, 2020.

The ASCO Post Staff

Saad Z. Usmani, MD: In My Experience Question 2

During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma?

Recorded April 24, 2020.

The ASCO Post Staff

Jacek Jassem, MD, PhD, on Fighting COVID-19 and Cancer: The View From Poland

Jacek Jassem, MD, PhD, of the Medical University of Gdansk, and an international editor on The ASCO Post Editorial Board, talks about the situation in Poland, how his institution is coping, and the adjustments the staff has made to deliver quality cancer care. Filmed April 17, 2020.